Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment.
A possible influence of Chlamydia pneumoniae seropositivity on the clinical course of peripheral arterial occlusive disease (PAOD) has not been investigated previously. Though roxithromycin therapy was found to inhibit progression of PAOD, the nature of this effect (antibiotic or anti-inflammatory) has remained elusive. The course of PAOD was prospectively assessed in elderly men during 4 years, comparing 51 C. pneumoniae seropositive (IgG>/=1:128) with 46 seronegative patients (IgG<1:64 and IgA<1:32). Twenty of the seropositive patients were treated with roxithromycin (400 mg daily) for 4 weeks. Limitation of the walking distance to 200 m or less was observed in 55% of the seropositive untreated patients as compared to 30% of both, seronegative and macrolide-treated patients. The number of invasive revascularizations per patient was 1.7 in the seropositive untreated group as compared to 0.5 in the seronegative and the macrolide-treated group. Considering possible confounding variables, such as classical vascular risk factors, ordinal regression analyses showed a significant association of C. pneumoniae seropositivity with limitation of the walking distance (p=0.027) and need for invasive revascularization (p=0.037). The effect of macrolide treatment on these outcome measures was marked (p<0.001 and p=0.040, respectively) during 2.7 years but decreased in the second part of the observation period. This study provides good evidence that C. pneumoniae are involved in the progression of PAOD and that antibiotic treatment directed against C. pneumoniae is effective in inhibiting this process.
Krayenbuehl
Pierre-Alexandre
PA
Department of Internal Medicine, Medical Policlinic, University Hospital, CH-8091 Zurich, Switzerland.
Wiesli
Peter
P
Maly
Friedrich E
FE
Vetter
Wilhelm
W
Schulthess
Georg
G
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000907:Antibodies, Bacterial / Q000097:blood; D001157:Arterial Occlusive Diseases / Q000382:microbiology / Q000517:prevention & control*; D001161:Arteriosclerosis / Q000382:microbiology / Q000517:prevention & control; D023521:Chlamydophila Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016993:Chlamydophila pneumoniae / Q000276:immunology / Q000302:isolation & purification*; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015575:Roxithromycin / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D015575:Roxithromycin